SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of REVLIMID (lenalidomide) at the American Society of Hematology 49th Annual Meeting, considered the premier educational and scientific event in the hematology/oncology international community, in Atlanta, GA from December 8-11, 2007.
